The HinduHealth
FDA issues four observations at Gland Pharma facility
The United States Food and Drug Administration issued four inspection observations after an unannounced review of current good manufacturing practices at Gland Pharma’s formulation facility in Dundigal, near Hyderabad. Inspectors visited from October 12 through October 23.
This card is an AI-assisted summary of reporting published by The Hindu. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.